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The prevalence of cardiovascular disease is continuously rising 
throughout Africa.1-5 The epidemiological transition impelling 
the developing world towards more non-communicable diseases, 
and especially cardiovascular disease, has been attributed to 
westernisation, reduced physical activity, obesity and the growing 
prevalence of cardiovascular risk factors.1 Although the prevalence 
of cardiovascular diseases is at present less than in the developed 
world, an enormous rise in the near future, and also that most of the 
increase will come from developing nations (especially Africa), has 
been predicted.6 The African INTERHEART Study,7 which looked 
at the contribution of conventional risk factors among subjects with 
developed coronary heart disease (CHD), found that 90% of these 
subjects had the conventional risk factors of smoking, diabetes 
mellitus (DM), hypertension, abdominal obesity and dyslipidaemia. 
This finding further highlights a similar pathway in the evolution of 
cardiovascular diseases.
Hypertension and diabetes are related to one another in many 
ways. Both can individually and jointly increase cardiovascular 
risk, morbidity and mortality of individual subjects.5 Heart disease 
(especially CHD) is a major cause of morbidity and mortality among 
subjects with abnormal glucose tolerance.9 The National Cholesterol 
Education Programme Adult Treatment Panel III views diabetes as 
being a cardiovascular risk factor equivalent to hypertension.10
It has been suggested that impaired glucose tolerance develops 
slowly among hypertensive subjects.11 There are few reports on 
the pattern of CHD risk factors among hypertensive subjects with 
impaired glucose tolerance in Africa. However, studies have shown 
that impaired glucose tolerance is more prevalent among hypertensive 
subjects than normotensive subjects.11,12
We studied the epidemiology of conventional CHD risk factors 
among hypertensive subjects with abnormal fasting glucose and those 
with normal fasting glucose.
Material and methods
One hundred and twenty consecutive newly presenting subjects with 
systemic hypertension were recruited from the Cardiology Clinic 
of Ladoke Akintola University Teaching Hospital (LAUTECH) 
in Osogbo, Nigeria. Hypertension was diagnosed when blood 
pressure was persistently ≥140/90 mmHg. The investigators took 
blood pressures using standardised protocols.13 Eighty age- and sex-
matched normotensive subjects who were not previously diagnosed 
hypertensive subjects and whose blood pressures were persistently 
≥140/90 mmHg were recruited among hospital staff and patients’ 
relatives after informed consent was obtained.
Each subject had a relevant clinical history taken, including 
demographic parameters, age, gender, occupation, past history of 
hypertension and DM, smoking history, alcohol intake, and family 
history of hypertension and diabetes. Past history of early morning 
facial puffiness, frothiness of urine or passage of smoky urine was 
taken to rule out renal causes of secondary hypertension. Other 
causes of secondary hypertension were ruled out by appropriate 
history, and any suspected case was subsequently excluded. All the 
subjects had urinalysis and renal ultrasound.
Weight to the nearest 0.5 kg was taken by a standard weighing 
scale with the subjects in light clothing. Waist circumference was 
taken at the midpoint between the lowest rib and the anterior Corresponding author: A Akintunde (iakintunde2@yahoo.com)
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Background. Impaired fasting or glucose tolerance and/or diabetes 
can occur with hypertension, which theoretically predicts a worse 
cardiovascular risk profile, and consequently requires intensive 
cardiovasular risk management.
Objectives. To characterise the frequency of the occurence of 
conventional cardiovascular risk factors among hypertensive 
subjects with impaired fasting blood glucose.
Methods. We studied 120 hypertensive subjects and 80 age- 
and sex-matched normotensive controls. Relevant history, clinical 
examination, laboratory and other tests were undertaken. Body 
mass index was determined. Informed consent was obtained from 
all participants, and ethical approval was obtained.
Results. There was no statistically significant diference between 
the age and gender of the hypertensive subjects and the controls 
(55.1±10.83 v. 54.7±10.89 years, p=0.76). The serum fasting 
lipids were higher, but not statistically significantly, among the 
hypertensives than the controls (triglycerides 1.23±0.50 v. 1.22±0.48, 
p=0.900; total cholesterol 4.51±1.52 v. 4.38±0.84, p=0.842; LDL 
2.51±1.41 v. 2.4±0.63, p=0.811, respectively). The prevalence of 
impaired glucose tolerance among newly presenting hypertensive 
subjects was 30.0%. Hypertriglyceridaemia (38.9% v. 6.0%, p=0.038), 
hypo-HDL cholesterolaemia (52.7% v. 31.0%, p=0.028) and visceral 
obesity (52.8% v. 27.4%, p=0.036) were statistically more prevalent 
among hypertensive subjects with impaired glucose tolerance than 
among those with normal glucose tolerance.
Conclusion. The prevalence of impaired glucose tolerance among 
newly presenting hypertensive subjects is very high, and they 
have more clusters of cardiovascular risks than those without 
impaired glucose tolerance. The former therefore need intensive 
cardiovascular assessment and appropriate preventive and treatment 
modalities. Glucose parameters of newly presenting hypertensive 
subjects must be determined to evaluate their cardiovascular risk 
profile.
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superior illiac spine. Hip circumference was taken over the greater 
trochanters. The waist/hip ratio (WHR) was determined. Height 
was taken with a stadiometer. Body mass index (BMI) (kg/m2) was 
defined as weight/(height2). Obesity was defined as BMI >30 and/
or waist circumference >102 cm for men and >88 cm for women. A 
fasting serum lipid was also done to estimate the fasting serum total 
cholesterol, triglycerides, low-density lipoprotein (LDL) and high-
density lipoprotein (HDL). Low HDL was defined as <1.3 mmol/l 
for females and <1.03 mmol/l for males. Hypertriglyceridaemia 
was defined as triglycerides >1.7 mmol/l, and total cholesterol was 
considered high if >6.1 mmol/l. Fasting blood sugar was done using 
the glucose oxidase method after at least an 8-hour fast. Abnormal 
glucose tolerance was defined as fasting blood sugar ≥5.5 mmol/l 
according to the International Diabetes Federation criteria.14 Ethical 
clearance was obtained for the study.
Data were analysed using Statistical Package for Social Sciences 
(SPSS) 16.0 (Chicago, Ill.). Quantitative data were summarised as 
means ± SD, while qualitative data were summarised as frequency 
and percentages. Student’s t-test and the chi-square test were used 
appropriately. Statistical significance was taken as p<0.05.
Results
The clinical characteristics of  the study participants are as shown 
in Table I. Mean waist circumference, BMI, fasting blood glucose 
and waist/hip ratio were significantly higher among hypertensive 
subjects than normotensive controls. The distribution of major 
cardiovascular risk factor among hypertensive subjects with normal 
fasting glucose and those with impaired fasting glucose is shown in 
Table II. Hypertriglyceridaemia, low HDL, hyperchlesterolaemia and 
elevated LDL were significantly higher among hypertensive subjects 
with impaired fasting glucose than among hypertensive subjects 
with normal fasting glucose. Furthermore, hypertensive subjects 
with impaired fasting glucose had higher mean waist circumferences 
than those with normal fasting glucose, as shown in Table III. Other 
clinical characteristics were similar between these two groups.
Discussion
The frequency of occurence of impaired fasting glucose in the 
present study was 30.0%; this is a high figure and reinforces the 
interrelationship between hypertension, progresive insulin resistance 
and the development of DM, a finding that agrees with similar 
reports by Essien et al.11 who subjected hypertensive subjects to oral 
glucose tolerance tests and reported that 32. 8% of them had impaired 
glucose tolerance. In this and other studies,15 the basal blood glucose 
level was higher among hypertensive subjects than control subjects. 
It has also been shown that simple clinical parameters such as BMI, 
fasting glucose, and insulin levels can be used to predict the prescence 
of hyperinsulinaemia among hypertensive subjects. These tests 
may therefore be used to predict progression of abnormal glucose 
tolerance.15
The relationship between hypertension and diabetes is complex. 
Hypertension is considerably more prevalent in diabetic patients than 
in nondiabetics.16,17 Hypertensive patients are 2.5 times more likely to 
develop type 2 diabetes than their normotensive counterparts when 
matched to age, sex, ethnicity, adiposity, level of physical activity 
and family history.17,18 Suggested causes for the increased tendency 
to develop DM include altered insulin sensitivity of skeletal muscle 
tissue and reduced blood flow to skeletal muscle tissue owing to 
vascular hypertrophy, rarefaction and vasoconstriction.16,19
Impaired fasting glucose (IFG) and impaired glucose tolerance 
(IGT) are strong predictors of type 2 DM, cardiovascular diseases 
and other complications of DM.20,21 The Strong Heart Study has 
also shown that IFG and IGT are associated with a greatly increased 
risk of cardiovascular disease even in prehypertensive individuals.22 
Therefore, to identify high-risk individuals early, the glucose blood 
profile of hypertensive subjects should always be taken.23,24
Table I. Clinical characteristics of the study population
Parameter   Hypertensives (N=120)  Controls (N=80)   p-value
Age (years)  55.1±10.83    54.7±10.89    0.76
Gender
Male (%)  66 (55.0%)    47 (58.8%)
Female (%)  54 (45.0%)    35 (41.2%)    0.822
SBP (mmHg)  147.72±26.47   115.1±13.2    <0.001*
DBP (mmHg)  89.3±17.0    70.96±9.7    <0.001*
No. of smokers(%)  12 (10.0%)    1 (1.25%)    0.0023*
Waist (cm)
Male   93.72±12.64   84.1±6.93
Female   93.99±11.55   83.6±10.6    <0.001*
TC (mmol/l)  4.51±1.52    4.38±0.84    0.847
BMI (kg/m2)  26.9±5.31    23.9±3.5    <0.001*
LDL (mmol/l)  2.5±1.41    2.4±0.63    0.811
Triglycerides (mmol/l) 1.23±0.50    1.22±0.48    0.900
HDL (mmol/l)
Male   1.16±0.45    1.28±0.37
Female   1.25±0.49    1.18±0.47    0.642
FBS (mmol/l)  5.6±1.93    3.98±1.29    0.000*
PP (mmHg)  57.93±24.84   44.76±10.25   0.000*
WHR
Male   0.97±0.07    0.92±0.05
Female   0.92±0.08    0.89±0.05    0.01*
*Statistically significant.
SBP = systolic blood pressure; DBP = diastolic blood pressure; TC = total cholesterol; BMI = body mass index; LDL = low-density lipoprotein; HDL = high-density lipoprotein;  
FBS = fasting blood sugar; PP = pulse pressure; WHR = waist/hip ratio.
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The mean fasting lipid levels in this study were not statistically 
different among the hypertensive and normotensive subjects, 
although the hypertensive subjects tended to have a higher level 
of LDL, triglycerides and total cholesterol, and a lower level of 
HDL. Other authors have documented similar results among 
hypertensive subjects and normotensive counterparts.25 However, the 
proportion of smokers was statistically significantly higher among 
the hypertensive subjects. Comparing the hypertensive subjects with 
normal fasting glucose with those with impaired fasting glucose, the 
latter tended to have higher rates of hypertriglyceridaemia, hypo-
HDL-cholesterolaemia, elevated LDL, hypercholesterolaemia and 
visceral obesity than those who had normal fasting glucose (Table 
II). An association between visceral obesity, dyslipidaemia and 
hypertension has been described.26,27
Comparing clinical characteristics between the above two groups, 
visceral obesity as assessed by waist circumference was the only 
statistically significant demographic parameter contributing to the 
presence of impaired fasting glucose. Though subjects with impaired 
glucose tolerance were older, this study does not confirm the contribution 
of age to the presence of impaired glucose tolerance among hypertensive 
subjects. Other workers have documented increased prevalence 
of cardiovascular risk factors among hypertensive subjects.7,28-30 
The present study therefore suggests that hypertensive subjects with 
impaired fasting glucose may be at an increased cardiovascular 
risk owing to the tendency for more clustering among them of the 
major cardiovascular risk factors. Longitudinal studies are therefore 
necessary to document the pattern of  cardiovascular morbidity and 
mortality of these patients.
The study has some limitations. Firstly, it is hospital-based and may 
not truly respresent the population at large. Secondly, being a cross-
sectional study by design, it cannot associate causal relationships 
between the factors under study.
Conclusion
Hypertensive subjects with impaired glucose tolerance have a 
higher chance than those with normal fasting glucose of having 
many more of the other conventional cardiovascular risk factors. 
Hypertriglyceridaemia, hypercholesterolaemia, elevated LDL, 
visceral obesity and low HDL were more common among them 
than hypertensive subjects with normal fasting glucose. Prospective 
longitudinal studies are suggested to identify the associated pattern of 
cardiovascular risk among this population.
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